VC Outlook Positive On Biotech IPO, M&A Activity
This article was originally published in Start Up
Executive Summary
Things are looking up for biotech VCs. The third quarter of 2014 was the sixth consecutive quarter in which the number of US initial public offerings by venture-backed biotech firms was in the double digits, and pharmaceutical companies show no sign that they're done sourcing R&D via mergers and acquisitions.